




PHARMACEUTICAL 2023

Harmony Biosciences Holdings Inc.
Rank 114 of 446





RealRate

PHARMACEUTICAL 2023

Harmony Biosciences Holdings Inc. Rank 114 of 446



The relative strengths and weaknesses of Harmony Biosciences Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Harmony Biosciences Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Harmony Biosciences Holdings Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 185%, being 142% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	400,285
Cost of Goods Sold	83,481
Intangible Assets	160,953
Liabilities, Current	78,884
Liabilities, Non-Current	192,148
Other Assets	112,059
Other Compr. Net Income	-151
Other Expenses	2,503
Other Liabilities	0
Other Net Income	-15,500
Other Revenues	437,855
Property and Equipment	573
Research and Development	70,886
Selling, General and Administrative Expense	84,017

Output Variable	Value in 1000 USD
Assets	673,870
Liabilities	271,032
Expenses	240,887
Revenues	437,855
Stockholders Equity	402,838
Net Income	181,468
Comprehensive Net Income	181,392
Economic Capital Ratio	185%